
|Articles|March 1, 2007
iCo IND accepted
The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007.
Advertisement
The FDA has accepted iCoTherapeutics' Investigational New Drug (IND) application for iCo-007, a treatment for diabetic macular oedema (DME).
iCo-007 is a second generation antisense compound that targets c-Raf kinase messenger RNA and reduces the oedema by decreasing the signalling of growth factors such as VEGF that signal through the c-Raf kinase pathway.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











